• Return to Headlines

Lowest Debt-to-Capital Ratio in the Pharmaceuticals Industry Detected in Shares of Revance Therapeu (RVNC, COLL, AMPH, AGRX, AGN)

By David Diaz

Below are the three companies in the Pharmaceuticals industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Revance Therapeu ranks lowest with a a Debt-to-Capital ratio of 69.1%. Following is Collegium Pharma with a a Debt-to-Capital ratio of 140.1%. Amphastar Pharma ranks third lowest with a a Debt-to-Capital ratio of 1,226.5%.

Agile Therapeuti follows with a a Debt-to-Capital ratio of 2,260.2%, and Allergan Plc rounds out the bottom five with a a Debt-to-Capital ratio of 2,894.3%.

SmarTrend recommended that its subscribers protect gains by selling shares of Revance Therapeu on January 17th, 2019 by issuing a Downtrend alert when the shares were trading at $17.33. Since that call, shares of Revance Therapeu have fallen 19.3%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: lowest debt-to-capital ratio revance therapeu collegium pharma amphastar pharma agile therapeuti allergan plc

Ticker(s): RVNC COLL AMPH AGRX AGN